NASHVILLE, Tenn. David W. Haas, MD and Duane Smoot, MD discussed grant funding opportunities with the Tennessee Center for AIDS Research (TN-CFAR) at a town hall meeting held Monday at the Meharry-Vanderbilt Alliance.
TN-CFAR is accepting applications for two categories of grant support, Haas told those in attendance, the CFAR Research Project Award and the CFAR Mission Award. TN-CFAR will present two CFAR Research Project Awards, for up to $50,000 each, within a 12-month period. It will present a single CFAR Mission Award for up to $10,000 within a 12-month period.
"The Mission Award is intended to support applications that align with specific aims of TN-CFAR," Haas explained. "These include creating new opportunities for HIV clinical/translational research at Meharry, and between Meharry and Vanderbilt, supporting junior investigator career development, and work toward developing a new emphasis on HIV-focused community engaged research (CEnR)."
This also includes collaborative work with the Tennessee Department of Health.
Funding will begin as early as October 7, 2015. No cost extensions will be considered contingent on available funds to CFAR. Likelihood of leading to a new funded NIH research grant application will be weighed heavily when evaluating CFAR Research Project applications.
Full applications are due Sept. 7 and require a prior Letter of Intent.
Click here for more information.
About the Meharry-Vanderbilt Alliance
Founded in 1999, the Alliance bridges the institutions of Meharry Medical College and Vanderbilt University. Its mission is to enrich learning and advance clinical research by developing and supporting mutually beneficial partnerships between Meharry Medical College, Vanderbilt University and the communities they serve.
About the Tennessee Center for AIDS Research
The vision of the Tennessee CFAR is to have transformative impact locally, nationally and globally. Guided by this vision, the mission of the Tennessee CFAR is to coordinate institutional and community resources and focus efforts on high-priority targets to most effectively reduce the burden of HIV/AIDS and to generalize these benefits nationally and globally.
